When was Elicio founded?

Elicio was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Elicio located?

Elicio is headquartered in Cambridge, United States. It is registered at 451 D STREET, 5TH FLOOR,BOSTON,2210,MA.

How many employees does Elicio have?

As of Aug 31, 2026, the latest employee count at Elicio is 47.

Is Elicio a funded company?

Elicio is a funded company, having raised a total of $47.4M across 11 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 07, 2012.

When was the latest funding round of Elicio?

Elicio's latest funding was a $***** Post IPO round on Dec 22, 2023, with participation from 0 investor.

Where does Elicio rank among its competitors?

Elicio ranks 12th amongst 3349 active competitors, of which 1124 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Elicio?

Elicio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Elicio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of vaccines for treating cancer. The company has developed lymph node targeted cell therapy activators, immunomodulators, and vaccines using the Amphiphile platform to control the immune signals and activate the immune system against cancer.

Website: elicio.com
Email ID: *****@elicio.com
Phone Number: +1 **********
Registered Address: 451 D STREET, 5TH FLOOR,BOSTON,2210,MA

Key Metrics

Founded Year

2012

Location

Cambridge, United States

Stage

Public

Total Funding

$47.4M in 11 rounds

Latest Funding Round

Post IPO, Dec 22, 2023, $*****

Investors

Dreavent & 6 more

Ranked

12^th among 3349 active competitors

Employee Count

47 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2998 more

Exit Details

Public

View Elicio's full profile

Elicio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Elicio Therapeutics, Inc. CIN: 1601485 , United States, Active		-	-	-
VEDANTRA PHARMACEUTICALS, INC. CIN: 0001555192 , United States, Active		-	5 (As on Dec 31, 2017)	-

Elicio got listed on Feb 05, 2021.

Click here to take a look at Elicio's IPO in detail

Elicio has raised a total funding of $47.4M over 11 rounds. Its first funding round was on May 07, 2012. Elicio has 7 institutional investors.

Here is the list of recent funding rounds of Elicio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 22, 2023	4956211	Post IPO	2849460	9110304	4546009	2301340
Sep 07, 2023	5325955	Grant (prize money)	4728544	8900516	5628643	Giresearchfoundation
Nov 02, 2022	5743910	Post IPO	2211252	7990396	6149167	8726392

Access funding benchmarks and valuations. Sign up today!

View details of Elicio's funding rounds and investors

The founders of Elicio is Darrell Irvine.

Here are the details of Elicio's key team members:

Darrell Irvine: Founder of Elicio and founder of 2 other companies, Ankyra and Strand Therapeutics.
Contact Info: 1 email address

View details of Elicio's Founder profiles and Board Members

Elicio's employee count trend

Elicio has 47 employees as of Aug 26. Here is Elicio's employee count trend over the years:

Uncover Elicio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elicio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Elicio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
12th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	63/100